Trial · NCT03759184
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Treatment-emergent Adverse Events (AEs) Related to Recombinant Human Interleukin-15 (rhIL-15) | 28 days or 4 weeks (cycle 1) | adverse events | NUMBER | |
| PRIMARY | Number of Treatment-emergent Adverse Events (AEs) Related to Obinutuzumab | 28 days or 4 weeks (cycle 1) | adverse events | NUMBER | |
| PRIMARY | Number of Participants With a Grades 3-5 Dose-limiting Toxicity (DLT) of Continuous Intravenous (CIV) Recombinant Human Interleukin-15 (rhIL-15) Treatment | 28 days or 4 weeks (cycle 1) | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants With a Grade 3-5 Dose-limiting Toxicity (DLT) With Intravenous (IV) Obinutuzumab Treatment | 28 days or 4 weeks (cycle 1) | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin-15 (rhIL-15) Administration | 28 days or 4 weeks (cycle 1) | This outcome measure was not done. The MTD was not found because the study was closed after \> 1 year of inactivity and only one participant was enrolled. | ||
| PRIMARY | Maximum Tolerated Dose (MTD) of Intravenous (IV) Obinutuzumab Treatment | 28 days or 4 weeks (cycle 1) | This outcome measure was not done. The MTD was not found because the study was closed after \> 1 year of inactivity and only one participant was enrolled. | ||
| SECONDARY | Duration of Response (DOR) | time measurement criteria are met for CR, CRi, or PR whichever is recorded first until the first date that recurrent of progressive disease is objectively documented or death, approximately 27 months | Months | MEDIAN | |
| SECONDARY | Overall Response Rate | 6 cycles (each cycle is 28 days or 4 weeks) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Event-free Survival (EFS) | Approximately 8 months | There is no confidence interval with 1 sample result. | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) | Approximately 27 months | There is no full range with 1 sample result. | Months | MEDIAN |
| SECONDARY | Progression-free Survival (PFS) | Approximately 8 months | There is no full range with 1 sample result. | Months | MEDIAN |
| OTHER_PRE_SPECIFIED | Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | Date treatment consent signed to date off study, approximately 27 months and 11 days. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03759184/outcomes